Quarterly Report (10-q)

Date : 02/13/2018 @ 8:36AM
Source : Edgar (US Regulatory)
Stock : Lotus Bio-technology Development Corp. (PC) (LBTD)
Quote : 0.0125  0.0 (0.00%) @ 4:09PM
Lotus Bio-Technology share price Chart

Quarterly Report (10-q)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 10-Q


[X]

QUARTERLY REPORT UNDER TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED

 December 31/2017


OR


[  ]

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


Commission File Number 000-54745


LOTUS BIO-TECHNOLOGY DEVELOPMENT CORP.

(Exact name of registrant as specified in its charter)


Nevada

(State of incorporation)


Unit 02 5/F Hankow Rd

Tsim, Sha Tsui,

Kowloon, Hong Kong

(Address of principal executive offices)


(852) 554 3668

(Registrant's telephone number)


Indicate by check mark whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the last 90 days.     YES [X]     NO [   ]


Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (SS 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).     YES [   ]     NO [X]


Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or   a smaller reporting company. See the definitions of "large accelerated filer, "accelerated filer," "non-accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):


Large Accelerated Filer

[   ]

Accelerated Filer

[   ]

Non-accelerated Filer  (Do not check if smaller reporting company)

[   ]

Smaller Reporting Company

[X]


Indicate  by check mark whether  the registrant  is a shell company  (as defined  in Rule  12b-2 of the Exchange  Act).

YES [  ]

NO [x  ]


As of December 31, 2017, there were 782,775,500 shares of the registrant's $0.00001 par value common stock issued and outstanding.



1




TABLE OF CONTENTS

 

Page

 

 

 

 

PART I.  FINANCIAL INFORMATION

 

 

 

 

ITEM 1.

FINANCIAL STATEMENTS.

3

 

 

 

 

Condensed Balance Sheets -   Unaudited

3

 

 

 

 

Condensed Statements of Operations -   Unaudited

4

 

 

 

 

Condensed Statements of Cash Flows -   Unaudited

5

 

 

 

 

Notes to the Financial Statements -   Unaudited

6

 

 

 

ITEM 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF

 

FINANCIAL CONDITION

 

AND RESULTS OF OPERATION.

9

 

 

 

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES

11

ABOUT MARKET RISK.

 

 

 

ITEM 4.

CONTROLS AND PROCEDURES.

11

 

 

 

ITEM 5.

OTHER INFORMATION

11

 

 

 

 

PART II.  OTHER INFORMATION

 

 

 

 

ITEM 1A.

RISK FACTORS.

12

 

 

 

ITEM 6.

EXHIBITS.

12

 

 

 

Signatures

 

13




2





LOTUS BIO-TECHNOLOGY DEVELOPMENT CORP.

Balance Sheet

(Unaudited)

 

 

 

 

 

 

Dec 30

 

Dec 301

 

 

 

 

 

 

2016

 

2017

 

 

 

 

 

 

$

 

$

ASSETS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current Assets

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

 

 

 

50,005 

 

Total current assets

 

 

 

 

50,005 

 

 

 

 

 

 

 

 

 

Capital Assets

 

 

 

 

 

 

 

 

Property and equipment, net

 

 

 

3,820 

 

5,458 

 

Total capital assets

 

 

 

3,821 

 

5,458 

 

 

 

 

 

 

 

 

 

TOTAL ASSETS

 

 

 

 

3,821 

 

55,463 

 

 

 

 

 

 

 

 

 

LIABILITIES AND SHAREHOLDERS' EQUITY

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

Accounts payable and accrued liabilities

 

 

20,333 

 

15,313 

 

Due to related parties

 

 

 

67,448 

 

51,458 

 

Total current liabilities

 

 

 

87,781 

 

66,771 

 

 

 

 

 

 

 

 

 

TOTAL LIABILITIES

 

 

 

87,781 

 

66,771 

Stockholder's equity (Deficiency)

 

 

 

 

 

 

 

Share capital

 

 

 

 

 

 

 

 

Authorized:

 

 

 

 

 

 

 

 

100,000,000 preferred shares, par value $0.00001

 

 

 

 

 

 

800,000,000 common shares, par value $0.00001

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issued and outstanding:

 

 

 

 

 

 

 

Nil preferred shares

 

 

 

 

 

 

 

782,775,500 common shares

 

 

 

828 

 

828 

 

Additional paid-in capital

 

 

 

867,263 

 

867,263 

 

 

 

 

 

 

 

 

 

 

Accumulated deficit

 

 

 

(952,051)

 

(929,399)

 

Total stockholders' equity (deficit)

 

 

(83,960)

 

(61,308)

 

 

 

 

 

 

 

 

 

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

3,821 

 

55,463 


The accompanying notes are an integral part of these financial statements.



3





LOTUS BIO-TECHNOLOGY DEVELOPMENT CORP.

Statement of Operations

(Unaudited)

 

 

 

 

 

Nine Months

 

Nine Months

 

Three Months

 

Three Months

 

 

 

 

 

Ended

 

Ended

 

Ended

 

Ended

 

 

 

 

 

Dec 31

 

Sept 30

 

Dec 31

 

Sept 30

 

 

 

 

 

2017

 

2017

 

2017

 

2017

 

 

 

 

 

$

 

$

 

$

 

$

Expenses

 

 

 

 

 

 

 

 

 

 

 

Accounting and legal

 

 

10,581 

 

9775 

 

6,969 

 

4,349 

      

Officer Compensation

 

 

4,500 

 

 

 

 

Amortization

 

 

 

1,638 

 

 

546 

 

 

Filing and registration

 

 

20 

 

 

 

 

Public Relations Communication

 

 

4,860 

 

 

4,860 

 

 

Stock transfer management

 

 

1,053 

 

2,925 

 

610 

 

2,180 

Earnings (Loss) from operations

 

 

(22,652)

 

(12,700)

 

(12,985)

 

(6,529)

 

 

 

 

 

 

 

 

 

 

 

 

Net loss and comprehensive loss for the year

 

(22,652)

 

(12,700)

 

(12,985)

 

(6,529)

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted loss per share

 

 

(0.00)

 

(0.00)

 

(0.00)

 

(0.00)

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of common shares outstanding

 

 

 

 

 

 

 

 

Basic and diluted

 

 

 

782,775,500 

 

181,275,000 

 

82,775,000 

 

181,275,000 


The accompanying notes are an integral part of these financial statements.



4





LOTUS BIO-TECHNOLOGY DEVELOPMENT CORP.

Statement of Cash Flows

(Unaudited)

 

 

 

 

 

 

 

Nine Months

 

Nine Months

 

 

 

 

 

 

 

 

Ended

 

Ended

 

 

 

 

 

 

 

 

Dec 31

 

Sept 30

 

 

 

 

 

 

 

 

2017

 

2017

 

 

 

 

 

 

 

 

$

 

$

 

Cash flows from operating activities

 

 

 

 

 

 

 

 

Net income (Loss)

 

 

 

 

(22,652)

 

(12,700)

 

 

Changes in non-cash working capital

 

 

 

 

 

 

 

 

  Accounts payable and accrued liabilities

 

 

 

520 

 

6,030 

 

 

  Amortization

 

 

 

 

 

1638 

 

 

 

Net cash provided by (used in) operating activities

 

 

(20,494)

 

(6,670)

 

Cash flows from investing activities

 

 

 

 

 

 

 

 

  Purchase of equipment

 

 

 

 

 

(6,550)

 

 

Net cash provided by (used in) financing activities

 

 

 

(6,550)

 

Cash flows from financing activities

 

 

 

 

 

 

 

 

  Due to related parties

 

 

 

 

20,490 

 

11,716 

 

 

Net cash provided by (used in) financing activities

 

 

20,490 

 

11,716 

 

Increase (Decrease) in cash and cash equivalents

 

 

 

(4)

 

(1,504)

 

Cash and cash equivalents , beginning of period

 

 

 

 

1,505 

 

Cash and cash equivalents , end of period

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUPPLEMENTAL CASH FLOW INFORMATION

 

 

 

 

 

 

Cash paid for interest

 

 

 

 

 

 

Cash paid for income taxes

 

 

 

 

 

 

Total cash paid for interest and income taxes

 

 

 

 

 


The accompanying notes are an integral part of these financial statements.



5




LOTUS BIOTECH DEVELOPMENT CORP.

Notes to the Financial Statements

(Unaudited)


1.   DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION


Lotus Bio-Technology Development Corp (“we”, “our”, the “Company”) was formed on March 24, 2011 with planned principal operations as an independent motion picture producer.  In 2016, the Company has shifted its focus and began exploring opportunities in the organic growth and farming sector in China.


In May of 2016, the Company has changed its name, president and business direction and entered the organic bio development space.


On May 7 th , 2016, The Company also signed a marketing and distribution agreement with Hunan Canshi in China. Lotus Bio-Technology will provide Marketing, Sales and distribution for organic related products produced exclusively by Hunan Canshi. The term of the agreement is 10 years.  General terms of the agreement state that Lotus will provide; Marketing, sales and distribution for Hunan Canshi and Hunan Canshi will provide a variety of Organic related products, Both Hunan Canshi and Lotus Bio-Technology intend to collaborate on a variety of business related issues such as promotion of products through social media and corporate website, development of joint marketing materials and training and support for all staff. The agreement also states that subsidiary company is to be created of which Lotus will own 51% in the newly established Hong Kong Entity As of today that process has not completed.


The accompanying unaudited interim financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all the information required to be included in a complete set of financial statements in accordance with accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the nine months ended December 31, 2017are not necessarily indicative of the results that may be expected for the fiscal year ending March 31, 2018.


2. GOING CONCERN


The Company’s interim unaudited financial statements are prepared using generally accepted accounting principles applicable to a going concern which contemplates realization of assets and liquidation of liabilities in the normal course of business. As shown in the accompanying financial statements, the Company has incurred net loss of $22,652 for the nine months ended December 31, 2017. The Company has not generated any operating revenues to date, has a working capital deficit and existence is dependent upon management’s ability to develop profitable operations. These conditions raise substantial doubt that the Company will be able to continue as a going concern. These financial statements do not include any adjustments that might result from this uncertainty.


Our activities to date have been supported by equity financing and demand loans from our major shareholder. Management continues to seek funding from its shareholders and other qualified investors to pursue its business plan and new course of action.


Loss Per Share


Loss per  share  is  computed  using  the  weighted  average  number  of shares outstanding during  the  period.  We have adopted ASC 260, "Earnings Per Share".  Diluted loss per share for year ended March 31, 2017 is equivalent to basic loss per share as there was no potential dilutive equity instrument.



6




Foreign Currency Transactions


The Company's functional currency is Canadian dollars and its reporting currency is the United States dollar.


The Company’s financial statements are translated from its functional currency, Canadian dollars, to the reporting currency, United States dollars, using the current rate method. Assets and liabilities are translated using the current rate in effect at the balance sheet date and revenues and expenses are translated at the average rate for the period. Adjustments resulting from the translation, if any, are included in cumulative other comprehensive income (loss) in stockholders’ equity. At Jun 30, 2017, the Company did not have any other comprehensive income (loss).


Capital Stock – share structure


The corporation’s articles pertaining to Stock has been amended as of Nov 16, 2017 to increase the authorized capital stock to 800,000,000 shares of common stock having par value of $0.00001 per   share. The amendment was made and approved by the Company’s Board of Directors on July 15, 2015. The Board of Directors have 83.3% of common stock which have 83.3% voting in favor of this amendment. The corporation’s articles pertaining to Stock has been amended as of July 21, 2015 to keep the authorized capital stock to 100,000,000 shares of preferred stock having par value of $0.00001 per share.  The Board of Directors have 83.3% of common stock which have 83.3% voting in favor in keeping the preferred stock to 100,000,000 shares.


Stock-Based Compensation


The Company adopted ASC 718, Compensation – Stock-Based Compensation , to account for its stock options and similar equity instruments issued.  Accordingly, compensation costs attributable to stock options or similar equity instruments granted are measured at the fair value at the grant date, and expensed over the expected vesting period.  ASC 718 requires excess tax benefits be reported as a financing cash inflow rather than as a reduction of taxes paid.  We did not grant any stock options during the period from March 24, 2011 (inception) to December 31, 2016


Comprehensive Income


We adopted ASC 220, Comprehensive Income , which establishes standards for reporting and display of comprehensive income, its components and accumulated balances.  We are disclosing this information on our Statement of Stockholders' Equity.  Comprehensive income comprises equity except those resulting from investments by owners and distributions to owners.  We have no elements of "other comprehensive income” from March 24, 2011 (inception) to December 31, 2017


3. DUE TO RELATED PARTIES


As at Dec 31, 2017 the balance due to a majority shareholder was $71,754. The amount due to the major shareholder is unsecured, non-interest bearing and due on demand.


As at Dec 31, 2017 the balance due to other related third parties was $25,694.



7





4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Unaudited Interim Financial Statements

 

The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. This report on Form 10-Q should be read in conjunction with the Company's audited financial statements and notes thereto included in the Company's Annual Report on Form 10-K, for the fiscal year ended March 31, 2017, as filed with the Securities and Exchange Commission ("SEC") on July 15, 2017.

 

In the opinion of management, all adjustments consisting of normal recurring entries necessary for a fair statement of the periods presented for: (a) the financial position; (b) the result of operations; and (c) cash flows, have been made in order to make the financial statements presented not misleading. The results of operations for such interim periods are not necessarily indicative of operations for a full year.

 

Basis of Presentation

 

The Financial Statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The Financial Statements have been prepared using the accrual basis of accounting in accordance with Generally Accepted Accounting Principles (“GAAP”) of the United States.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.

 

Cash and Cash Equivalents

 

Cash and cash equivalents include cash in banks, management, are subject to an insignificant risk of loss in value. The Company had $50,005 in cash and cash equivalents as of Dec 31, 2017 and March 31, 2017 respectively.


Principal of Consolidation


These consolidated financial statements include the accounts of Lotus Bio-technology Development.  All intercompany balances and transactions have been eliminated in consolidation.


5.

SUBSEQUENT EVENTS


As at Dec 31, 2017, there is no subsequent events. The Company has evaluated all subsequent events through the filing date of the form 10Q for appropriate accounting and disclosure, and there is no subsequent event disclosure required.



8




Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION.


Forward-Looking Statements


Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements.” These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.


Management’s Discussion and Analysis of Financial Condition and Results of Operations


Lotus Bio-Technology Development Corp was formed under the laws of the State of Nevada. We have not commenced our planned principal operations.


Plan of Operation


All the information following is based upon estimates. We are a startup company, or in other words, a company with a limited operating history, since our operations have been limited to incorporating Lotus Bio- Technology Development Corp; issuing stock to Zoltan Nagy, our previous officer and director; developing our business plan; began developing our website;  Since then we have spent all the money raised in our public offering.


Lotus Bio-Technology is actively seeking new opportunities in the emerging bio-natural industry in China. Our mandate is to partner with companies that are in the organic growth sector that meet the criteria we have set out to grow various plants under strict organic standards. Plants that can be refined into various products which are completely natural and strike a balance between affordability while being produced from an environmentally responsible manner. Products that are void of pesticides, synthetic fertilizers, anti-biotics, growth hormones and any other dangerous chemicals.


In anticipation of the Company's growth strategy, Lotus Bio-Technology intends to establish a corporate office in Yong Zhou City to serve as our China headquarters for its daily business activity. Our local office is currently in Point Roberts, WA.


Limited operating history; need for additional capital


There is no historical financial information about us upon which to base an evaluation of our performance. We are in a start-up stage operations and have not generated any revenues. We cannot guarantee we will be successful in our business operations. Our business is subject to risks inherent in the establishment of a new business enterprise, including limited capital resources and possible cost overruns due to price and cost increases in services and products. To become profitable and competitive, we must sell our products, and execute our business plan. We are not seeking equity financing at present time.



9




We have no assurance that future financing will be available to us on acceptable terms. If financing is not available on satisfactory terms, we may be unable to continue operations. Equity financing could result in additional dilution to existing shareholders.


Results of operations


Results of operations for the three and six months ended December 31, 2017 and June 30, 2017


We have not earned any revenues during the three and six months ended Dec 31, 2017. We incurred expenses and a net loss in the amount of $8,111 for the three months ended Sept 30, 2017. Our expenses during the three months ended Sept 30, 2017 consisted of accounting and legal fees of $8,111. By comparison, we incurred a net loss of $4,019 for the three months ended Sept 30, 2017. We incurred expenses and a net loss in the amount of $4,621 for the six months ended Dec 31, 2017. Our expenses during the six months ended June 30, 2017 consisted of accounting and legal fees of $7,426, general and administrative fees of $20, stock transfer management fee of $1745, and amortization expense of $846. By comparison, we incurred a net loss of $12,171 for the six months ended Sept 30, 2017.


Our losses are attributable to operating expenses together with a lack of any revenues.       


Liquidity and capital resources


As of the date of this report, we have yet to generate any revenues from our business operations.


As of Dec 31, 2017, our total current assets were $1 and our total current liabilities were $87,781. Accordingly, we had a working capital deficit of $87,781 as of Dec 31, 2017.


During the six months ended Dec 31, 2017, the former sole officer and director of the Company paid no expenses on behalf of the Company. As of Dec 31, 2017, $87,454 was due to the previous sole officer and director. The amount due was unsecured, non-interest bearing and due on demand.


Going Concern


As discussed in the notes to our financial statements, we have not established a source of revenue. This has raised substantial doubt to our auditors about our ability to continue as a going concern. Without realization of additional capital, it would be unlikely for us to continue as a going concern.


Our activities to date have been supported by equity financing and demand loans from our major shareholder. Management continues to seek funding from its shareholders and other qualified investors to pursue its business plan and new course of action.


Off Balance Sheet Arrangements


As of Dec 31, 2017, there were no off balance sheet arrangements.




10





ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.


We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.


ITEM 4. CONTROLS AND PROCEDURES.


Under the supervision and with the participation of our management, including the Principal Executive Officer and Principal Financial Officer, we have evaluated the effectiveness of our disclosure controls and procedures as required by Exchange Act Rule 13a-15(b) as of September 30, 2017. Based on that evaluation, the Principal Executive Officer and Principal Financial Officer have concluded that these disclosure controls and procedures are not effective.


There were no changes in our internal control over financial reporting during the quarter ended Dec 31, 2017, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.


Item 5. OTHER INFORMATION


On May 7 th , 2016, The Company also signed a marketing and distribution agreement with Hunan Canshi in China. Lotus Bio-Technology will provide Marketing, Sales and distribution for organic related products produced exclusively by Hunan Canshi. The agreement is 10 years. General terms of the agreement state that Lotus will provide; Marketing, sales and distribution for Hunan Canshi and Hunan Canshi will provide a variety of Organic related products, Both Hunan Canshi and Lotus Bio-Technology intend to collaborate on a variety of business related issues such as promotion of products through social media and corporate website, development of joint marketing materials and training and support for all staff. The agreement also states that subsidiary company is to be created of which Lotus will own 51% in a newly established Hong Kong entity. As of today, that process has not completed.




11




PART II - OTHER INFORMATION


ITEM 1A.

RISK FACTORS.


We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.


ITEM 6.

EXHIBITS.


Incorporated by reference

Filed

Exhibit

Document Description

Form

Date

Number

herewith


3.1


Articles of Incorporation.


S-1


6/10/11


3.1

 

3.2

Bylaws.

S-1

6/10/11

3.2

 

14.1

Code of Ethics.

10-K

6/22/12

14.1

 

31.1

Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 312 of the Sarbanes- Oxley Act of 2002.

 

 

 

X

32.1

Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

X

99.2

Audit Committee Charter.

10-K

6/22/12

99.2

 

99.3

Disclosure Committee Charter.

10-K

6/22/12

99.3

 

101.INS

XBRL Instance Document.

 

 

 

 

101.SCH

XBRL Taxonomy Extension – Schema.

 

 

 

 

101.CAL

XBRL Taxonomy Extension – Calculations.

 

 

 

 

101.DEF

XBRL Taxonomy Extension – Definitions.

 

 

 

 

101.LAB

XBRL Taxonomy Extension – Labels.

 

 

 

 

101.PRE

XBRL Taxonomy Extension – Presentation.

 

 

 

 




12




SIGNATURES


Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on this 13th day of February, 2018.


 

 

 

 

 

 

 

LOTUS BIO-TECHNOLOGY DEVELOPMENT CORP

 

 

 

 

BY:

William Ko

_________

 

 

William Ko

 

 

President, Principal Executive Officer, Principal Financial Officer, Principal Accounting Officer, Secretary, Treasurer and sole member of the Board of Directors




13



Lotus Bio-Technology (OTCBB:LBTD)
Historical Stock Chart

1 Year : From Feb 2017 to Feb 2018

Click Here for more Lotus Bio-Technology Charts.

Lotus Bio-Technology (OTCBB:LBTD)
Intraday Stock Chart

Today : Saturday 24 February 2018

Click Here for more Lotus Bio-Technology Charts.

Latest LBTD Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V:us D:20180224 05:56:47